The New Ireland Fund, Inc. Announces Payment of Quarterly

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
225
The New Ireland Fund, Inc. Announces Payment of Quarterly Distribution

BOSTON, MA--(Marketwired - Jun 30, 2017) - The New Ireland Fund, Inc. ( NYSE : IRL ) (the "Fund"), a closed-end fund, today announced that it paid on June 30, 2017, a distribution of US$0.30985 per share to all shareholders of record as of June 23, 2017.

Your Fund's distribution policy (the "Distribution Policy") is to provide investors with a stable quarterly distribution out of current income, supplemented by realized capital gains and, to the extent necessary, paid-in capital.

Under U.S. tax rules applicable to the Fund, the amount and character of distributable income for each fiscal year can be finally determined only as of the end of the Fund's fiscal year. However, under Section 19 of the Investment Company Act of 1940, as amended (the "1940 Act") and related Rules, the Fund may be required to indicate to shareholders the source of certain distributions to shareholders.

The following table sets forth the estimated amounts of the sources of the distribution for purposes of Section 19 of the 1940 Act and the Rules adopted thereunder. The table has been computed based on generally accepted accounting principles. The table includes estimated amounts and percentages for the distribution to be paid on June 30, 2017, as well as the estimated cumulative distributions declared fiscal year to date (11/1/2016 - 5/31/2017), from the following sources: net investment income; net realized short-term capital gains; net realized long-term capital gains; and return of capital. The estimated composition of the distributions may vary from quarter to quarter because the estimated composition may be impacted by future income, expenses and realized gains and losses on securities.

               
  Estimated Amounts of Current Quarterly Distribution per share ($)   Estimated Amounts of Current Quarterly Distribution per share (%)   Estimated Amounts of Fiscal Year to Date Cumulative Distributions per share ($)   Estimated Amounts of Fiscal Year to Date Cumulative Distributions per share (%)
Net Investment Income -   -   -   -
Net Realized Short- Term Capital Gains * -   -   -   -
Net Realized Long-Term Capital Gains $0.30985   100%   $0.83125   100%
Return of Capital -   -   -   -
Total (per common share) $0.30985   100%   $0.83125   100%
*including currency gains              

Shareholders should not draw any conclusions about the Fund's investment performance from the amount of this distribution or from the terms of the Fund's Distribution Policy, which is to provide investors with a stable quarterly distribution.

The amounts and sources of distributions reported in this notice are only estimates and are not being provided for tax reporting purposes. The final determination of the source of all distributions in 2017 will be made after year-end. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund's investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes.

The following table provides the Fund's total return performance based on net asset value (NAV) over various time periods compared to the Fund's annualized and cumulative distribution rates.

   
Average Annual Total Return on NAV for the 5 Year Period Ending 5/31/2017 1 20.84%
Current Fiscal Period's Annualized Distribution Rate on NAV 2 9.62%
Fiscal Year to Date (11/1/2016 to 5/31/2017)
Cumulative Total Return on NAV 1 26.40%
Cumulative Distribution Rate on NAV 2 4.81%
1 Return data is net of all fund expenses and fees and assumes the reinvestment of all distributions reinvested at prices obtained under the Fund's dividend reinvestment plan. 
2 Based on the Fund's NAV as of May 31, 2017. 

While NAV performance may be indicative of the Fund's investment performance, it does not measure the value of a shareholder's investment in the Fund. The value of a shareholder's investment in the Fund is determined by the Fund's market price, which is based on the supply and demand for the Fund's shares in the open market.

Pursuant to an exemptive order granted to the Fund by the Securities and Exchange Commission on August 19, 2014, the Fund may distribute any long-term capital gains more frequently than the limits provided in Section 19(b) under the 1940 Act and Rule 19b-1 thereunder. Therefore, distributions paid by the Fund during the year may include net income, short-term capital gains, long-term capital gains and/or a return of capital. Net income dividends and short-term capital gain dividends, while generally taxable at ordinary income rates, may be eligible, to the extent of qualified dividend income earned by the Fund, to be taxed at a lower long-term capital gains rate. If the total distributions made in any calendar year exceed investment company taxable income and net capital gain, such excess distributed amount would be treated as ordinary income to the extent of the Fund's current and accumulated earnings and profits. Distributions in excess of the earnings and profits would first be a tax-free return of capital to the extent of the adjusted tax basis in the shares. After such adjusted tax basis is reduced to zero, the distribution would constitute capital gain (assuming the shares are held as capital assets).

The payment of distributions in accordance with the Distribution Policy may result in a decrease in the Fund's net assets. A decrease in the Fund's net assets may cause an increase in the Fund's annual operating expenses and a decrease in the Fund's market price per share to the extent the market price correlates closely to the Fund's net asset value per share. The Distribution Policy may also negatively affect the Fund's investment activities to the extent that the Fund is required to hold larger cash positions than it typically would hold or to the extent that the Fund must liquidate securities that it would not have sold or hold securities that it would liquidate, for the purpose of paying the distribution. The Distribution Policy may, under certain circumstances, cause the amounts of taxable distributions to exceed the levels required to be distributed under the Internal Revenue Code ( i.e. , to the extent the Fund has capital losses in any taxable year, such losses may be carried forward to reduce the amount of capital gains required to be distributed in future years; if distributions in a year exceed the amount minimally required to be distributed under the tax rules, such excess will be taxable as ordinary income to the extent loss carryforwards reduce the required amount of capital gains distributions in that year). The Fund's Board of Directors has the right to amend, suspend or terminate the Distribution Policy at any time. The amendment, suspension or termination of the Distribution Policy may affect the Fund's market price per share. Investors should consult their tax advisor regarding federal, state and local tax considerations that may be applicable in their particular circumstances.

Closed-end funds are traded on the secondary market through one of the stock exchanges. The Fund's investment return and principal value will fluctuate so that an investor's shares may be worth more or less than the original cost. Shares of closed-end funds may trade above (a premium) or below (a discount) the net asset value (NAV) of the fund's portfolio. There is no assurance that a fund will achieve its investment objective. Past performance does not guarantee future results.

The Fund is managed by KBI Global Investors (North America) Ltd, a subsidiary of KBI Global Investors Ltd, and is listed on the New York Stock Exchange under the ticker symbol - IRL. For further information, please contact the Fund at (800) 468-6475 or investor.query@newirelandfund.com .

Website: www.newirelandfund.com

The New Ireland Fund, Inc. (800) 468-6475 investor.query@newirelandfund.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

USPS Honors 150 Years of the U.S. Coast Guard Academy

Updated Category News Views 7

Honoring Tradition and Service The good ol’ U.S. Postal Service is at it again, giving a tip of the hat to a slice of American military heritage. This time, they’re putting out a new stamp to celebrate the 150th anniversary of the U.S. Coast Guard Academy. And you know where they did the honors? Right there on Custom House Pier in New London, Connecticut, a place that...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 3

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Damp or Dry: The Battle for Healthy Air in Colorado

Updated Category News Views 5

The Hidden Cost of Colorado's Dry Air Dry climate isn't just a seasonal inconvenience—it's a real hidden cost to living comfortably and healthily in Colorado. With winters colder than a brass monkey's tail and summers that don't offer much relief in terms of humidity, your home's air quality is on the front line. So, what's the financial tale here, and how do you come...

Continue Reading
OneOdio Showcases Innovation at IFA 2026 in Berlin

Updated Category News Views 4

Echoes from Berlin IFA 2026 in Berlin was a cacophony of innovation, as OneOdio wrapped up its showcase with a bang. Boasting interactive activities and live DJ sets, the event echoed OneOdio's drive to meld advanced audio technology with the pulsating needs of music pros and everyday listeners. You couldn’t miss the excitement in the air at Booth 217. Tech Unplugged:...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 4

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Ajman Spotlights Tourism at Arabian Travel Market 2026

Updated Category News Views 3

Ajman: A Tourism Gem in the Making Swinging into the Arabian Travel Market 2026, Ajman isn't just a footnote in the UAE's tourism playbook anymore, it's gunning for the spotlight. There's a flurry of activity as the Ajman Department of Tourism, Culture and Media rolls up its sleeves to flaunt the emirate's kaleidoscope of attractions to the world's tourism brass. Going...

Continue Reading
SMPL Faces Legal Drama: What Investors Need to Know

Updated Category News Views 5

Investors Swim Against the Current With SMPL Picture this: You’re sipping your morning coffee, glancing through stocks, only to choke on your bagel when The Simply Good Foods Company (NASDAQ: SMPL) pops up with some less-than-palatable news. A class action is brewing, shouting out to investors who took the bait from October 24, 2024, to April 8, 2026. If you’re one of...

Continue Reading
U.S. Green Beret's Mission: Clearing Landmines in Ukraine

Updated Category News Views 3

The Rise of "Safe Ground" on Prime Video This isn't your typical feel-good story—it’s about grit and the unending fight for 'normalcy' where war left scars. Safe Ground, now streaming on Prime Video, showcases Ryan Hendrickson, a U.S. Army Green Beret whose story takes a sharp turn after stepping on an IED in 2010. The day he almost became just another statistic...

Continue Reading
PureHealth's Acid Reflux Solutions: An Investor's Insight

Updated Category News Views 3

Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 2

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading

Top 5 Most Recently Viewed Articles

Crawford Nickel Project Advances Under Ontario's New Framework

Updated Category News Views 90

Introduction to the Crawford Nickel Project Canada Nickel Company Inc. has exciting news regarding its Crawford Nickel Project, which has been officially recognized by the Province of Ontario. This milestone comes as part of Ontario's One Project, One Process (1P1P) framework, a major step forward for the mining sector. Understanding the One Project, One Process Framework...

Continue Reading
TeamBridge Secures $28 Million to Enhance Workforce Technology

Updated Category News Views 124

TeamBridge Secures $28 Million to Revolutionize the Hourly Workforce TeamBridge, a rapidly expanding Workforce Operating System (Workforce OS), has successfully raised $28 million in Series B funding. This round was led by Mayfield, with considerable backing from existing investors, including General Catalyst and Abstract Ventures. This funding represents a significant...

Continue Reading
Innovative AI Collaboration for Breakthrough Cancer Therapies

Updated Category News Views 116

Pierre Fabre Laboratories and Iktos Unite for Oncology Drug Discovery Pierre Fabre Laboratories and Iktos have announced an exciting new collaboration aimed at transforming drug discovery in oncology. This partnership harnesses the strengths of both companies to utilize advanced AI technologies for developing new small-molecule drug candidates. Together, they plan to make...

Continue Reading
Vitamin Angels Partners with Walgreens to Improve Lives Globally

Updated Category News Views 529

Vitamin Angels and Walgreens: A Transformative Partnership Vitamin Angels and Walgreens have reached a remarkable achievement, positively impacting the lives of 500 million women and children across the globe. Over the course of their partnership, they have dedicated themselves to providing essential vitamins and minerals primarily to underserved communities within the...

Continue Reading
Forecasting the Growth of India's Flourishing Fluoropolymer Market

Updated Category News Views 104

Understanding the Flourishing Fluoropolymer Market in India India's fluoropolymer market is on an impressive trajectory, forecasted to reach a valuation of US$ 799.28 million by 2033 from US$ 425.12 million in 2024, reflecting an annual growth rate (CAGR) of 7.46% during the years ahead. This surge can be attributed to various factors, including technological...

Continue Reading